The reimbursement environment in Europe

17/05/2013

Sophia Tickell

In our market access themed month, Sophia Tickell comments on the reimbursement landscape in healthcare across Europe. For decades, Europe's labs and R&D centres produced world-beating innovation. A different innovation of...

The enemy within

17/05/2013

Sam Olsen

Sam Olsen warns that the greatest threat to Pharmaceutical and Biotech corporate Intellectual Property (IP) security comes from within. He says that that companies should not just consider if their...

Pharma gets social: Novartis has content, but no engagement

16/05/2013

Daniel Ghinn

In his latest article, Daniel Ghinn takes a look at Novartis' social media channels and questions whether there is a missed opportunity for the pharma company as it is not...

Malaysia pharmaceutical market update, 2013

16/05/2013

Ames Gross

Ames Gross of Pacific Bridge Medical provides an overview of the pharmaceutical market in Malaysia. Malaysia's pharmaceutical market is currently worth $3 billion, more than three times the size of the...

Janssen’s ulcerative colitis drug approved by US FDA

17/05/2013

Hannah Blake

Janssen Biotech, one of Johnson & Johnson's pharma companies, has announced the FDA approval of its ulcerative colitis drug, Simponi for use in the US. The FDA has approved Simponi (golimumab)...

Sanofi reports positive phase 3 myelofibrosis study results

17/05/2013

Hannah Blake

Sanofi has announced that its rare disease treatment to treat myelofibrosis showed positive results in a late-stage phase 3 clinical trial. The French drugmaker's pivotal study JAKARTA was evaluating the JAK2...

Bayer’s prostate cancer drug wins early FDA approval

16/05/2013

Hannah Blake

Bayer's new prostate cancer drug has been approved in the US three months ahead of schedule through the FDA's priority review system. Xofigo (radium Ra 223 dichloride) has been approved to...

Merck KGaA, Quintiles sign 5-year clinical trial agreement

16/05/2013

Hannah Blake

Merck Serono, a division of German's Merck KGaA, has announced a new five-year clinical development agreement with Quintiles. This strategic collaboration is the first-of-its-kind between a biopharma company and a...

Open access in medical journals - interv…

Executive perspectives: Bruno Strigini

Outcomes shape the new payer networks fo…

Marcelo Fantoni

The definition of the payer and the way in which healthcare spending decisions are made is changing, as complex networks of payers and clinicians become the new stakeholders with which...

Publishing white papers on pharmaphorum

Paul Tunnah

As a new feature on pharmaphorum, we unveil pharmaceutical industry white papers as part of our media section. Download this one page document to understand how to publish your deep...